Nanjing Leads Biolabs Co. Ltd. announced that its investigational drug LBL-034, a GPRC5D/CD3 bispecific T-cell engager, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma. The Fast Track Designation is intended to facilitate the development and expedite the review of drugs that address unmet medical needs for serious or life-threatening conditions. The designation provides benefits such as more frequent interactions with the FDA and the possibility of priority and rolling review of marketing applications. No other beneficiary organizations were mentioned in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260128-12002968), on January 28, 2026, and is solely responsible for the information contained therein.